CAR T cells targeting CEA that were used to treat three patients with metastatic colorectal cancer showed a promising outcome in at least one patient; however, severe transient colitis was induced, most probably due to the CEA presence in the colonic mucosa [62]. The gene discussed is CEACAM5; the disease is colitis.